Alkermes plc. SEC filings ALKS

Alkermes plc. has 1,000 filings in SEC EDGAR's recent list, going back to May 4, 2017. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.

Alkermes plc. SEC filings
Form Description Filed Period
DFAN14A Filing Jun 28, 2023 —
DFAN14A Filing Jun 28, 2023 —
DFAN14A Filing Jun 26, 2023 —
DFAN14A Filing Jun 22, 2023 —
DFAN14A Filing Jun 20, 2023 —
DFAN14A Filing Jun 15, 2023 —
DFAN14A Filing Jun 13, 2023 —
DFAN14A Filing Jun 9, 2023 —
DFAN14A Form dfan14a Jun 6, 2023 —
DFAN14A Filing Jun 5, 2023 —
DEFC14A Filing Jun 2, 2023 —
DEFC14A Filing May 25, 2023 —
PRRN14A Form prrn14a May 22, 2023 —
CORRESP Letter to the SEC May 19, 2023 —
UPLOAD Letter from the SEC May 19, 2023 —
PRER14A Filing May 19, 2023 —
UPLOAD Letter from the SEC May 16, 2023 —
PREC14A Form prec14a May 15, 2023 —
PREC14A Filing May 8, 2023 —
DEFC14A Filing Jun 6, 2022 —
PREC14A Filing May 26, 2022 —
CT ORDER Filing May 19, 2020 —
SEC STAFF LETTER Filing Feb 27, 2020 —
SEC STAFF LETTER Filing Feb 10, 2020 —
CT ORDER Filing Dec 4, 2019 —
CT ORDER Filing Mar 14, 2019 —
CT ORDER Filing Nov 29, 2018 —
CT ORDER Filing May 30, 2018 —
CT ORDER Filing Mar 19, 2018 —
CT ORDER Filing Jun 13, 2017 —

Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ALKS (Nasdaq)
Fiscal year ends
December 31
Headquarters
Dublin 4, Ireland
SEC filer status
Large accelerated filer
SEC CIK
1520262
Former names
ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.